Table 2 Mean (standard deviation) values at baseline and 12 months after the Can Do treatment with relative difference (percentage of baseline) (mean, standard error of the mean) and P value for comparison (paired t-test) for self-efficacy [multiple sclerosis self-efficacy scale (MSSES)], impact on participation and autonomy [impact on participation and autonomy questionnaire (IPA)], HRQoL [multiple sclerosis quality of life-54 items (MSQoL-54)], anxiety and depression [Hospital anxiety and depression scale (HADS)], and fatigue [(modified fatigue impact scale-5 items (MFIS-5)] in the progressive group (N = 14); Δ, difference
Progressive group (N = 14) | Baseline | 12th month | % Δ | P |
|---|---|---|---|---|
MSSES function (N = 13) | 56.24 (22.36) | 53.65 (25.55) | −5.34 (5.34) | 0.438 |
MSSES control (N = 13) | 47.80 (15.00) | 52.78 (20.01) | +7.96 (8.15) | 0.297 |
IPA limitations (N = 14) | 2.76 (0.68) | 2.72 (0.66) | −0.30 (6.45) | 0.720 |
IPA problems (N = 14) | 1.90 (0.34) | 1.84 (0.46) | −1.58 (6.48) | 0.631 |
MSQoL-54 physical (N = 5) | 38.12 (6.46) | 45.54 (18.12) | +4.18 (13.05) | 0.719 |
MSQoL-54 mental (N = 10) | 53.83 (17.32) | 57.03 (14.29) | +8.06 (9.51) | 0.649 |
HADS anxiety (N = 13) | 7.21 (3.38) | 6.31 (4.55) | −6.99 (12.78) | 0.477 |
HADS depression (N = 14) | 6.71 (3.89) | 6.50 (3.78) | +25.59 (25.11) | 0.843 |
MFIS-5 (N = 14) | 12.57 (4.03) | 11.93 (3.36) | −1.00 (6.60) | 0.395 |